1 Min Read
May 10 (Reuters) - Karo Pharma Ab:
* Q1 EBITDA amounted to MSEK 43.7 (9.3)
* Q1 net sales amounted to MSEK 139.3 (82.3), growth was mainly due to acquisitions Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.